KR20070086075A - 글리코겐 신타제 키나제-3 억제제 - Google Patents

글리코겐 신타제 키나제-3 억제제 Download PDF

Info

Publication number
KR20070086075A
KR20070086075A KR1020077013214A KR20077013214A KR20070086075A KR 20070086075 A KR20070086075 A KR 20070086075A KR 1020077013214 A KR1020077013214 A KR 1020077013214A KR 20077013214 A KR20077013214 A KR 20077013214A KR 20070086075 A KR20070086075 A KR 20070086075A
Authority
KR
South Korea
Prior art keywords
gsk
compound
group
activity
amino
Prior art date
Application number
KR1020077013214A
Other languages
English (en)
Korean (ko)
Inventor
하지트 엘다르-핑켈만
모세 포트노이
Original Assignee
텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피. filed Critical 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피.
Publication of KR20070086075A publication Critical patent/KR20070086075A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020077013214A 2004-11-18 2005-11-20 글리코겐 신타제 키나제-3 억제제 KR20070086075A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62854204P 2004-11-18 2004-11-18
US60/628,542 2004-11-18

Publications (1)

Publication Number Publication Date
KR20070086075A true KR20070086075A (ko) 2007-08-27

Family

ID=35655492

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077013214A KR20070086075A (ko) 2004-11-18 2005-11-20 글리코겐 신타제 키나제-3 억제제

Country Status (7)

Country Link
EP (1) EP1824468A2 (fr)
JP (1) JP4954888B2 (fr)
KR (1) KR20070086075A (fr)
CN (1) CN101098686B (fr)
AU (1) AU2005234687A1 (fr)
CA (1) CA2587732A1 (fr)
WO (1) WO2006054298A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2625201A (en) 2000-01-03 2001-07-16 Ramot University Authority For Applied Research And Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
US7378432B2 (en) 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
CA2509374A1 (fr) 2002-12-12 2004-06-24 Tel Aviv University Future Technology Development L.P. Inhibiteurs de la glycogene synthase kinase-3
GB0714941D0 (en) * 2007-08-01 2007-09-12 Imp Innovations Ltd Inhibitors
KR101592871B1 (ko) * 2013-03-19 2016-02-11 부산대학교 산학협력단 Akt에 의해 활성화되는 글리코겐 합성효소 키나아제 베타 억제용 펩타이드
CN105884827B (zh) * 2015-02-13 2018-03-13 山东轩竹医药科技有限公司 嘧啶酰胺衍生物及其盐

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2625201A (en) * 2000-01-03 2001-07-16 Ramot University Authority For Applied Research And Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
CA2509374A1 (fr) * 2002-12-12 2004-06-24 Tel Aviv University Future Technology Development L.P. Inhibiteurs de la glycogene synthase kinase-3
CA2530111A1 (fr) * 2003-06-27 2005-01-06 Tel-Aviv University Future Technology Development L.P. Inhibiteurs de la glycogene synthase kinase-3

Also Published As

Publication number Publication date
WO2006054298A2 (fr) 2006-05-26
JP2008520649A (ja) 2008-06-19
EP1824468A2 (fr) 2007-08-29
AU2005234687A1 (en) 2005-12-08
CN101098686A (zh) 2008-01-02
CN101098686B (zh) 2012-03-14
JP4954888B2 (ja) 2012-06-20
CA2587732A1 (fr) 2006-05-26
WO2006054298A3 (fr) 2006-06-29

Similar Documents

Publication Publication Date Title
US7378432B2 (en) Glycogen synthase kinase-3 inhibitors
KR20060018902A (ko) 글리코겐 신타제 키나제-3 억제제
US7833974B2 (en) Glycogen synthase kinase-3 inhibitors
US5321030A (en) Creatine analogs having antiviral activity
RU2450000C2 (ru) N-(2-тиазолил)амидные производные в качестве ингибиторов gsk-3
KR20070086075A (ko) 글리코겐 신타제 키나제-3 억제제
WO2012016186A1 (fr) Inhibiteurs de kinases macrocycliques et leurs utilisations
JP2004505054A (ja) 知覚を改善する医薬品としての選択的ｐｄｅ２インヒビター
JP2002541065A5 (fr)
WO2018053373A1 (fr) Utilisations d'inhibiteurs de kinase inductible par un sel (sik) pour traiter l'ostéoporose
Bunik et al. Analysis of the protein binding sites for thiamin and its derivatives to elucidate the molecular mechanisms of the noncoenzyme action of thiamin (vitamin B1)
CA2634217A1 (fr) Composes de distribution d'acides amines ou de peptides a activite antioxydante dans les mitochondries et leur utilisation
CN107406485A (zh) 用于治疗癌症的肽
US9688719B2 (en) Glycogen synthase kinase-3 inhibitors
WO2016017844A1 (fr) Peptide présentant une inhibition de l'activation et la différenciation des ostéoclastes, et son utilisation
US7799753B2 (en) Bisubstrate inhibitors of protein tyrosine kinases as therapeutic agents
US9821008B2 (en) Inhibitors of ERCC1-XPF and methods of using the same
Sun et al. Characteristic and Import Mechanism of Protein Nuclear Translocation.
EP3829589A1 (fr) Procédés d'activation de cellules microgliales
CN108774167A (zh) 一种含金刚烷取代基的吡啶类化合物及其在制备抗肿瘤药物中的用途
JP2001514662A (ja) ヒトｓｒｃ ＳＨ２ドメインの拮抗方法

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid